The two GPER targets (EGFR and PI3K) are activators or initiators of downstream signaling pathways and thus, could serve as primary foci in the GPER-mediated therapy for most of the cancers we studied and for some diabetic conditions. The gene discussed is GPER1; the disease is cancer.